| __timestamp | HUTCHMED (China) Limited | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 33472000 | 21226345 |
| Thursday, January 1, 2015 | 47368000 | 87718074 |
| Friday, January 1, 2016 | 66871000 | 93831530 |
| Sunday, January 1, 2017 | 50675000 | 79419009 |
| Monday, January 1, 2018 | 78821000 | 132166913 |
| Tuesday, January 1, 2019 | 91944000 | 89124838 |
| Wednesday, January 1, 2020 | 111234000 | 65782137 |
| Friday, January 1, 2021 | 207447000 | 88845513 |
| Saturday, January 1, 2022 | 267587000 | 134715000 |
| Sunday, January 1, 2023 | 303055000 | 180142000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Intra-Cellular Therapies, Inc. and HUTCHMED (China) Limited have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, HUTCHMED's R&D expenses surged by over 800%, peaking in 2023. This reflects their aggressive push into new therapeutic areas. In contrast, Intra-Cellular Therapies, Inc. saw a more modest increase of around 750% during the same period, with notable spikes in 2018 and 2023. This suggests a strategic focus on refining existing treatments. As these companies continue to innovate, their R&D spending patterns offer valuable insights into their future directions and potential breakthroughs. Understanding these trends is crucial for investors and stakeholders aiming to navigate the dynamic biotech landscape.
R&D Insights: How Eli Lilly and Company and Intra-Cellular Therapies, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Novartis AG and HUTCHMED (China) Limited
argenx SE vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Xenon Pharmaceuticals Inc.
Intra-Cellular Therapies, Inc. or MorphoSys AG: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Dynavax Technologies Corporation
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Viridian Therapeutics, Inc.
R&D Spending Showdown: Insmed Incorporated vs HUTCHMED (China) Limited
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs HUTCHMED (China) Limited
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc.